The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey
The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecolo...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
29 January 2025
|
| In: |
BMC cancer
Year: 2025, Volume: 25, Pages: 170-1-170-9 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-025-13432-5 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-025-13432-5
|
| Author Notes: | Maximilian Riedel, Helene Herrmann, Thomas Bartl, Anna-Maria Rossner, Anna Tatzber, Chiara Flethe, Dario Zocholl, Barbara Schmalfeldt, Jalid Sehouli and Klaus Pietzner |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1937619664 | ||
| 003 | DE-627 | ||
| 005 | 20251212122346.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251002s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-025-13432-5 |2 doi | |
| 035 | |a (DE-627)1937619664 | ||
| 035 | |a (DE-599)KXP1937619664 | ||
| 035 | |a (OCoLC)1559712875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Riedel, Maximilian |e VerfasserIn |0 (DE-588)1278491740 |0 (DE-627)1831410133 |4 aut | |
| 245 | 1 | 4 | |a The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology |b a JAGO/NOGGO survey |c Maximilian Riedel, Helene Herrmann, Thomas Bartl, Anna-Maria Rossner, Anna Tatzber, Chiara Flethe, Dario Zocholl, Barbara Schmalfeldt, Jalid Sehouli and Klaus Pietzner |
| 264 | 1 | |c 29 January 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.10.2025 | ||
| 520 | |a The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecologic oncology are very limited. The aim of this survey was to provide a real-world overview of the experiences and the current state of irAE management of ICIs in Germany, Switzerland, and Austria. | ||
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Gynecologic oncology | |
| 650 | 4 | |a Immune adverse events | |
| 650 | 4 | |a Immune checkpoint blockade | |
| 700 | 1 | |a Herrmann, Helene |e VerfasserIn |0 (DE-588)1378061829 |0 (DE-627)193761963X |4 aut | |
| 700 | 1 | |a Bartl, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rossner, Anna-Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tatzber, Anna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Flethe, Chiara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zocholl, Dario |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmalfeldt, Barbara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sehouli, Jalid |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pietzner, Klaus |e VerfasserIn |0 (DE-588)1077116292 |0 (DE-627)836031792 |0 (DE-576)445995157 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 25(2025), Artikel-ID 170, Seite 170-1-170-9 |h Online-Ressource |w (DE-627)326643710 |w (DE-600)2041352-X |w (DE-576)107014645 |x 1471-2407 |7 nnas |a The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology a JAGO/NOGGO survey |
| 773 | 1 | 8 | |g volume:25 |g year:2025 |g elocationid:170 |g pages:170-1-170-9 |g extent:9 |a The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology a JAGO/NOGGO survey |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12885-025-13432-5 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20251002 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1378061829 |a Herrmann, Helene |m 1378061829:Herrmann, Helene |d 910000 |d 910400 |e 910000PH1378061829 |e 910400PH1378061829 |k 0/910000/ |k 1/910000/910400/ |p 2 | ||
| 999 | |a KXP-PPN1937619664 |e 4779873681 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 02.10.2025"],"language":["eng"],"recId":"1937619664","person":[{"family":"Riedel","given":"Maximilian","display":"Riedel, Maximilian","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Herrmann, Helene","given":"Helene","family":"Herrmann"},{"family":"Bartl","given":"Thomas","roleDisplay":"VerfasserIn","display":"Bartl, Thomas","role":"aut"},{"given":"Anna-Maria","family":"Rossner","role":"aut","display":"Rossner, Anna-Maria","roleDisplay":"VerfasserIn"},{"display":"Tatzber, Anna","roleDisplay":"VerfasserIn","role":"aut","family":"Tatzber","given":"Anna"},{"roleDisplay":"VerfasserIn","display":"Flethe, Chiara","role":"aut","family":"Flethe","given":"Chiara"},{"family":"Zocholl","given":"Dario","roleDisplay":"VerfasserIn","display":"Zocholl, Dario","role":"aut"},{"role":"aut","display":"Schmalfeldt, Barbara","roleDisplay":"VerfasserIn","given":"Barbara","family":"Schmalfeldt"},{"given":"Jalid","family":"Sehouli","role":"aut","display":"Sehouli, Jalid","roleDisplay":"VerfasserIn"},{"display":"Pietzner, Klaus","roleDisplay":"VerfasserIn","role":"aut","family":"Pietzner","given":"Klaus"}],"title":[{"title_sort":"implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology","title":"The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology","subtitle":"a JAGO/NOGGO survey"}],"physDesc":[{"noteIll":"Diagramme","extent":"9 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2041352-X"],"eki":["326643710"],"issn":["1471-2407"]},"origin":[{"publisher":"BioMed Central ; Springer","dateIssuedKey":"2001","dateIssuedDisp":"2001-","publisherPlace":"London ; Berlin ; Heidelberg"}],"part":{"volume":"25","text":"25(2025), Artikel-ID 170, Seite 170-1-170-9","extent":"9","year":"2025","pages":"170-1-170-9"},"pubHistory":["1.2001 -"],"recId":"326643710","language":["eng"],"note":["Gesehen am 22.05.20"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology a JAGO/NOGGO surveyBMC cancer","title":[{"title":"BMC cancer","title_sort":"BMC cancer"}]}],"name":{"displayForm":["Maximilian Riedel, Helene Herrmann, Thomas Bartl, Anna-Maria Rossner, Anna Tatzber, Chiara Flethe, Dario Zocholl, Barbara Schmalfeldt, Jalid Sehouli and Klaus Pietzner"]},"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"29 January 2025"}],"id":{"doi":["10.1186/s12885-025-13432-5"],"eki":["1937619664"]}} | ||
| SRT | |a RIEDELMAXIIMPLEMENTA2920 | ||